Navigation Links
Inovio Pharmaceuticals Reports Long-Term Immune Responses from Therapeutic Cervical Dysplasia and Cancer DNA Vaccine
Date:5/9/2011

ry.htm">electroporation device in a randomized, placebo-controlled, double-blind Phase II clinical study. We believe that these newly reported Phase I data showing long term persistence of antigen-specific T cells further support our confidence and  optimism for ultimately meeting the primary endpoint of this Phase II efficacy study: the clearance of CIN 2/3 lesions, measured at month 9, after three vaccinations at months 0, 1, and 3," concluded Dr. Kim.  

This recently initiated Phase II study will enroll 148 patients with CIN 2/3 or CIN 3 at approximately 25 study centers in the US, Korea, South Africa, Australia, and Canada. The study will also assess humoral and cell mediated immune responses to VGX-3100 in blood samples taken prior to the first vaccine dose and periodically thereafter. Cervical samples will be analyzed for evidence of immune responses in the cervix at baseline and subsequent intervals. Subjects will also be monitored for tolerability and safety.

The clinical trial protocol, HPV-003, is available at: http://clinicaltrials.gov/ct2/show/NCT01304524?term=NCT01304524&rank=1.

About Cervical Dysplasias/Cancers

Human papillomavirus (HPV) is the causative agent responsible for most cases of cervical cancer. At any given time, approximately 10% of women worldwide are infected with HPV. While roughly 70% of HPV infections are cleared by the body on its own, persistent HPV can lead to dysplasia, or premalignant changes in cells, of the cervix. Researchers have estimated the global prevalence of clinically pre-cancerous HPV infections at between 28 and 40 million. Persistent dysplasias may then progress to cancer. Every year, 510,000 cases of cervical cancer are diagnosed worldwide, and about 288,000 of the afflicted women, primarily in developing countries, die.

Preventive vaccines such as GARDASIL® and
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Inovio Pharmaceuticals Enters Phase II Clinical Trial with SynCon™ DNA Vaccine for Cervical Dysplasia Caused by HPV
2. Inovio Pharmaceuticals Foot-and-Mouth Disease DNA Vaccine Introduces Critical Advantages in Fight Against Most Serious Farm Animal Disease
3. Inovio Pharmaceuticals to Present at 13th Annual BIO CEO & Investor Conference
4. Vanda Pharmaceuticals Reports First Quarter 2011 Results
5. MAP Pharmaceuticals Reports First Quarter of 2011 Financial Results
6. Anadys Pharmaceuticals to Report First Quarter 2011 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2011 Financial Results
8. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2011 Financial Results
9. Keryx Biopharmaceuticals Announces Positive Final Data from Zerenex™ Short-Term Phase 3 Study
10. Optimer Pharmaceuticals and Clinical Investigators to Present Data at Upcoming Medical Meetings
11. Auxilium Pharmaceuticals to Announce First Quarter 2011 Results and Conduct Conference Call on Monday, May 9, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... BioSpecifics Technologies Corp. (OTC Bulletin Board: BSTC), a ... today announced that it has received notification from The ... been approved for listing on the NASDAQ Global Market. ... 2009 on NASDAQ at market open under the symbol ...
... 6 /PRNewswire-FirstCall/ - SemBioSys Genetics Inc. (TSX:SBS), a ... today announced it has received US$2,500,000 from MannKind ... the option agreement and issuance of 2,400,000 units ... The transaction provides MannKind with the option to ...
... Star Scientific (Nasdaq :STSI) announced today that its ... its Star Tobacco, Inc. subsidiary, recently completed a ... dissolvable smokeless tobacco to relieve cigarette withdrawal symptoms ... (NRT). The study, which included 49 cigarette smokers, ...
Cached Biology Technology:BioSpecifics Technologies Corp. Announces Listing on NASDAQ Global Market 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 2SemBioSys receives US$2.5 million from option agreement with MannKind for plant-produced insulin 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 2Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 3Star Scientific Announces Successful Completion of Product Satisfaction Study - Results Show Potential for Development and Manufacturing of New Pharmaceutical Product for Smoking and Smokeless Tobacco Cessation 4
(Date:4/15/2014)... Biologists at UC San Diego have succeeded in ... hormone responsible for growth and resistance to drought. ... studies to determine how the hormone helps plants ... by the continuing increase in the atmosphere,s carbon ... achievement appears in the April 15 issue of ...
(Date:4/15/2014)... Looking at the question of how social behavior has ... universities in Mainz and Basel have gained new insights ... simply compete for food. Rather the siblings share what ... absent," explained Dr. Jol Meunier of the Evolutionary Biology ... University of Mainz (JGU). The team of biologists from ...
(Date:4/15/2014)... (April 15, 2014) The American Association of Anatomists ... All awards will be presented during the Closing ... Hotel on Tuesday, April 29th at 7:30 p.m. during ... , The 2014 award winners are: , ... PhD, of the Icahn School of Medicine at Mount ...
Breaking Biology News(10 mins):Biologists develop nanosensors to visualize movements and distribution of plant hormone 2Sibling cooperation in earwig families gives clues to early evolution of social behavior 2American Association of Anatomists 2014 award winners 2
... Spanish scientists have analysed the temperature and salt levels of ... the evolution of each variable. Their research shows that, since ... hotter and saltier, and that, since the 1990s, this process ... deep layer of the Western Mediterranean increases by 0.002C, and ...
... Miami (UM) has been selected to receive a $1.4 ... to strengthen the UM undergraduate science education program. The ... will use the resources to help attract first-generation college ... sciences to pursue careers in science. , "HHMI ...
... of Oxford and Royal Holloway University of London have discovered that ... works best if applied to young plants and is enhanced by ... (20 May) in the open-access journal PLoS Pathogens . ... is a common method for controlling a variety of insect ...
Cached Biology News:Temperature and salt levels of the Western Mediterranean are on the increase 2UM receives 5th consecutive Howard Hughes Medical Institute grant for science education 2Study uncovers optimal ecology of bioinsecticide 2
...
Rabbit polyclonal antibody to NMDA NR2B [Tyr1336]...
ImmunoPure Plus Immobilized Protein G, , , , Support: Cross-linked 6%, beaded agarose , Capacity: > 20 mg human IgG/ml of gel ...
Mouse monoclonal antibody to FMN2 - formin 2...
Biology Products: